Caribou Biosciences, a clinical-stage CRISPR gene-editing company, announced that CEO Rachel Haurwitz will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The event will highlight Caribou's innovative chRDNA genome-editing technology and their off-the-shelf CAR-T cell therapies, vispa-cel and CB-011, aimed at treating hematologic cancers. Webcasts of the discussion will be available on Caribou's website for 30 days post-event, providing investors and stakeholders insight into their latest developments and clinical progress.
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
Ipsen Pharma conducted share buybacks from July 6 to July 10, 2026, purchasing a total of 28,541 shares. The average purchase price was €166.05 per share. These buybacks were made under Article 5 of the MAR regulation, indicating a structured repurch...
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
